Liquid biopsies and minimal residual disease in myeloid malignancies

Minimal residual disease (MRD) assessment through blood component sampling by liquid biopsies (LBs) is increasingly being investigated in myeloid malignancies. Blood components then undergo molecular analysis by flow cytometry or sequencing techniques and can be used as a powerful tool for prognosti...

Descripción completa

Detalles Bibliográficos
Autores principales: Allam, Sabine, Nasr, Kristina, Khalid, Farhan, Shah, Zunairah, Khan Suheb, Mahammed Ziauddin, Mulla, Sana, Vikash, Sindhu, Bou Zerdan, Maroun, Anwer, Faiz, Chaulagain, Chakra P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196237/
https://www.ncbi.nlm.nih.gov/pubmed/37213280
http://dx.doi.org/10.3389/fonc.2023.1164017

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10196237/
https://www.ncbi.nlm.nih.gov/pubmed/37213280
http://dx.doi.org/10.3389/fonc.2023.1164017

Ejemplares similares